US OptionsDetailed Quotes

STRO250117C7500

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Wesley10
    Wesley10
    Jan 7 09:01
    ☕️
    $Sutro Biopharma (STRO.US)$
    Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study...
    Jaguar8
    Jaguar8
    Dec 10, 2024 07:09
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
    Tuesday, 10th December at 8:00 am
    - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
    - These data confirm luvelta's robust response rate in patients with late-stage ovarian c...
    Trytosaveabit
    Trytosaveabit
    Nov 1, 2024 07:03
    Update
    $Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
    Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
    Jaguar8
    Jaguar8
    Nov 1, 2024 07:02
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
    Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
    Jaguar8
    Jaguar8
    Oct 10, 2024 15:06
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
    Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
Read more